Optiscan Submits InSpecta FDA Dossier
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has submitted a regulatory dossier to the U.S. FDA for its InSpecta® veterinary device, marking a significant step towards entering the U.S. veterinary market. This submission indicates the device's readiness for formal regulatory review and supports the expansion of clinical reference sites.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Initiates Head & Neck Cancer Imaging Study
- Optiscan Partners with ACL to Advance Digital Pathology
- Appendix 4E - Preliminary Final Report
Later from Optiscan Imaging
- Optiscan Receives $1.69m R&D Tax Refund
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Head and Neck Study Progressing Ahead of Schedule
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging